Pharmaceutical manufacturing depends on repeatable inspection. A tablet with a crack, chip, stain, discoloration or other visible anomaly can signal a problem that deserves attention before product moves further downstream. Human inspection remains valuable, but it is inherently variable and difficult to scale consistently across long runs, multiple products and changing operators. Computer vision offers…
Pfizer and AstraZeneca top annual pharma future-readiness rankings
As 2023 draws to a close, the pharma industry finds itself at an inflection point. On the one hand, stubbornly high inflation rates, a dearth of talent, supply chain hurdles, and a more challenging regulatory climate threaten profitability. But on the other, the rapid advances in areas ranging from cell and gene therapy and IT…
It’s time to rethink pharma supply chains
Global supply chains have arguably seen more disruption in the past year than they have seen in decades. Pharmaceutical supply chains were especially vulnerable in the early days of the COVID-19 pandemic, prompting a rethink of supply chain management for the industry. Another wrinkle is a recent executive order from President Biden, which prompted a…